Publications

  1. Ailawadhi S, Parrondo RD, Moustafa MA, LaPlant BR, Alegria V, Chapin D, Roy V, Sher T, Paulus A, Chanan-Khan AA. Ibrutinib, lenalidomide and dexamethasone in patients with relapsed and/or refractory multiple myeloma: Phase I trial results. Hematol Oncol. 2022 Apr 30. [Epub ahead of print]
    View PubMed
  2. Ailawadhi S, Swaika A, Advani P, Hodge D, Paulus A, Khera N, Hashmi SK, Alegria VR, Abdulazeez M, Bodepudi S, Jamwal K, Roy V, Sher T, Chanan-Khan A, Ailawadhi M. Awareness of myeloma care and the global impact of treatment: An international internet-based prospective study. J Oncol Pharm Pract. 2022 Mar; 28 (2):425-433 Epub 2021 Mar 09
    View PubMed
  3. Chini CCS, Peclat TR, Gomez LS, Zeidler JD, Warner GM, Kashyap S, Mazdeh DZ, Hayat F, Migaud ME, Paulus A, Chanan-Khan AA, Chini EN. Dihydronicotinamide Riboside Is a Potent NAD(+) Precursor Promoting a Pro-Inflammatory Phenotype in Macrophages. Front Immunol. 2022; 13:840246 Epub 2022 Feb 25
    View PubMed
  4. Jayakrishnan T, Aulakh S, Baksh M, Nguyen K, Ailawadhi M, Samreen A, Parrondo R, Sher T, Roy V, Manochakian R, Paulus A, Chanan-Khan A, Ailawadhi S. Landmark Cancer Clinical Trials and Real-World Patient Populations: Examining Race and Age Reporting. Cancers (Basel). 2021 Nov 18; 13 (22)
    View PubMed
  5. Kumar V, Ailawadhi M, Dutta N, Abdulazeez M, Aggarwal CS, Quintero G, Baksh M, Roy V, Sher T, Alegria V, Paulus A, Chanan-Khan A, Ailawadhi S. Trends in Early Mortality From Multiple Myeloma: A Population-Based Analysis. Clin Lymphoma Myeloma Leuk. 2021 May; 21 (5):e449-e455 Epub 2020 Dec 24
    View PubMed
  6. Ailawadhi S, Frank R, Ailawadhi M, Kanji Z, Jani P, Fiala M, Abdulazeez M, Ahmed S, Aggarwal CS, Aulakh S, Hodge D, Roy V, Alegria VR, Paulus A, Chanan-Khan A, Sher T. Utilization of radiation therapy in multiple myeloma: trends and changes in practice. Ann Hematol. 2021 Mar; 100 (3):735-741 Epub 2021 Jan 12
    View PubMed
  7. Gunaratne MDSK, Sahakian AJ, Abeykoon JP, Ansell SM, Gertz MA, Kapoor P, Paulus A, Ailawadhi S, Reeder CB, Witzig TE, Habermann TM, Novak AJ, Lacy MQ, Kyle RA, Go RS, Paludo J. Treatment facility volume and patient outcomes in Waldenstrom macroglobulinemia. Leuk Lymphoma. 2021 Feb; 62 (2):308-315 Epub 2020 Oct 15
    View PubMed
  8. Horenstein AL, Faini AC, Morandi F, Bracci C, Lanza F, Giuliani N, Paulus A, Malavasi F. The Circular Life of Human CD38: From Basic Science to Clinics and Back. Molecules. 2020 Oct 21; 25 (20)
    View PubMed
  9. Madamsetty VS, Paulus A, Akhtar S, Manna A, Rachamalla HR, Banerjee R, Mukhopadhyay D, Chanan-Khan A. Novel tumor-targeted liposomes comprised of an MDM2 antagonist plus proteasome inhibitor display anti-tumor activity in a xenograft model of bortezomib-resistant Waldenstrom macroglobulinemia. Leuk Lymphoma. 2020 Oct; 61 (10):2399-2408 Epub 2020 June 19
    View PubMed
  10. Iqbal M, Spaulding A, Niazi S, Wood C, Ahmed S, Jani P, Kharfan-Dabaja MA, Ayala E, Manochakian R, Ames S, Paulus A, Ailawadhi S, Roy V, Chanan-Khan A, Sher T. Impact of Depression and Anxiety on Opioid Use in Hospitalized Hematopoietic Cell Transplantation Recipients. Psychosomatics. 2020 Jul - Aug; 61 (4):363-370 Epub 2020 Mar 26
    View PubMed
  11. Manna A, Kellett T, Aulakh S, Lewis-Tuffin LJ, Dutta N, Knutson K, Chini E, Pinilla-Ibarz J, Lamanna N, Manochakian R, Malavasi F, Sher T, Chanan-Khan AA, Ailawadhi S, Paulus A. Targeting CD38 is lethal to Breg-like chronic lymphocytic leukemia cells and Tregs, but restores CD8+ T-cell responses. Blood Adv. 2020 May 26; 4 (10):2143-2157
    View PubMed
  12. Kumar V, Alhaj-Moustafa M, Bojanini L, Sher T, Roy V, Manochakian R, Vishnu P, Bodepudi S, Shareef Z, Ahmed S, Jani P, Paulus A, Grover A, Alegria VR, Ailawadhi M, Chanan-Khan A, Ailawadhi S. Timeliness of Initial Therapy in Multiple Myeloma: Trends and Factors Affecting Patient Care. JCO Oncol Pract. 2020 Apr; 16 (4):e341-e349 Epub 2020 Jan 21
    View PubMed
  13. Advani P, Paulus A, Ailawadhi S. Updates in prognostication and treatment of Waldenstrom's macroglobulinemia. Hematol Oncol Stem Cell Ther. 2019 Dec; 12 (4):179-188 Epub 2019 May 28
    View PubMed
  14. Ailawadhi S, Azzouqa AG, Hodge D, Cochuyt J, Jani P, Ahmed S, Sher T, Roy V, Ailawadhi M, Alegria VR, Manochakian R, Vishnu P, Grover A, Abdulazeez MF, Paulus A, Chanan-Khan A. Survival Trends in Young Patients With Multiple Myeloma: A Focus on Racial-Ethnic Minorities. Clin Lymphoma Myeloma Leuk. 2019 Oct; 19 (10):619-623 Epub 2019 June 26
    View PubMed
  15. Aulakh S, DeDeo MR, Free J, Rosenfeld SS, Quinones-Hinojosa A, Paulus A, Manna A, Manochakian R, Chanan-Khan AA, Ailawadhi S. Survival trends in glioblastoma and association with treating facility volume. J Clin Neurosci. 2019 Oct; 68:271-274 Epub 2019 May 24
    View PubMed
  16. Kumar V, Ailawadhi S, Bojanini L, Mehta A, Biswas S, Sher T, Roy V, Vishnu P, Marin-Acevedo J, Alegria VR, Paulus A, Aulakh S, Iqbal M, Manochakian R, Tan W, Chanan-Khan A, Ailawadhi M. Trends in the risk of second primary malignancies among survivors of chronic lymphocytic leukemia. Blood Cancer J. 2019 Sep 30; 9 (10):75 Epub 2019 Sept 30
    View PubMed
  17. Ailawadhi S, Sher T, Azzouqa AG, Meghji Z, Jain T, Jani P, Ahmed S, Diehl N, Roy V, Shah V, Hodge D, Ailawadhi M, Alegria VR, Paulus A, Chanan-Khan A, Fonseca R. Monoclonal antibody utilization characteristics in patients with multiple myeloma. Anticancer Drugs. 2019 Sep; 30 (8):859-865
    View PubMed
  18. Manna A, Aulakh S, Jani P, Ahmed S, Akhtar S, Coignet M, Heckman M, Meghji Z, Bhatia K, Sharma A, Sher T, Alegria V, Malavasi F, Chini EN, Chanan-Khan A, Ailawadhi S, Paulus A. Targeting CD38 Enhances the Antileukemic Activity of Ibrutinib in Chronic Lymphocytic Leukemia. Clin Cancer Res. 2019 Jul 1; 25 (13):3974-3985 Epub 2019 Apr 02
    View PubMed
  19. Ailawadhi S, Dholaria BR, Khurana S, Sher T, Alegria V, Paulus A, Ailawadhi M, Mehta A, Chanan-Khan A, Roy V. Outcomes of patients with simultaneous diagnosis of chronic lymphocytic leukaemia/small lymphocytic lymphoma and multiple myeloma. Br J Haematol. 2019 Apr; 185 (2):347-350 Epub 2018 July 05
    View PubMed
  20. Paulus A, Manna A, Akhtar S, Paulus SM, Sharma M, Coignet MV, Jiang L, Roy V, Witzig TE, Ansell SM, Allan J, Furman R, Aulakh S, Manochakian R, Ailawadhi S, Chanan-Khan AA, Sher T. Targeting CD38 with daratumumab is lethal to Waldenstrom macroglobulinaemia cells. Br J Haematol. 2018 Oct; 183 (2):196-211 Epub 2018 Aug 06
    View PubMed
  21. Laali KK, Greves WJ, Zwarycz AT, Correa Smits SJ, Troendle FJ, Borosky GL, Akhtar S, Manna A, Paulus A, Chanan-Khan A, Nukaya M, Kennedy GD. Synthesis, Computational Docking Study, and Biological Evaluation of a Library of Heterocyclic Curcuminoids with Remarkable Antitumor Activity. ChemMedChem. 2018 Sep 19; 13(18):1895-1908. Epub 2018 Aug 05.
    View PubMed
  22. Ailawadhi S, Frank RD, Sharma M, Menghani R, Temkit M, Paulus S, Khera N, Hashmi S, Advani P, Swaika A, Paulus A, Aslam N, Sher T, Roy V, Colon-Otero G, Chanan-Khan A. Trends in multiple myeloma presentation, management, cost of care, and outcomes in the Medicare population: A comprehensive look at racial disparities. Cancer. 2018 Apr 15; 124 (8):1710-1721 Epub 2018 Jan 23
    View PubMed
  23. Laali KK, Greves WJ, Correa-Smits SJ, Zwarycz AT, Bunge SD, Borosky GL, Manna A, Paulus A, Chanan-Khan A. Novel fluorinated curcuminoids and their pyrazole and isoxazole derivatives: Synthesis, structural studies, computational/docking and in-vitro bioassay Journal of Fluorine Chemistry. 2018; 206:82-98
  24. Ailawadhi S, Frank RD, Advani P, Swaika A, Temkit M, Menghani R, Sharma M, Meghji Z, Paulus S, Khera N, Hashmi SK, Paulus A, Kakar TS, Hodge DO, Colibaseanu DT, Vizzini MR, Roy V, Colon-Otero G, Chanan-Khan AA. Racial disparity in utilization of therapeutic modalities among multiple myeloma patients: a SEER-medicare analysis. Cancer Med. 2017 Dec; 6 (12):2876-2885 Epub 2017 Nov 03
    View PubMed
  25. Paulus A, Akhtar S, Yousaf H, Manna A, Paulus SM, Bashir Y, Caulfield TR, Kuranz-Blake M, Chitta K, Wang X, Asmann Y, Hudec R, Springer W, Ailawadhi S, Chanan-Khan A. Waldenstrom macroglobulinemia cells devoid of BTK(C481S) or CXCR4(WHIM-like) mutations acquire resistance to ibrutinib through upregulation of Bcl-2 and AKT resulting in vulnerability towards venetoclax or MK2206 treatment. Blood Cancer J. 2017 May 26; 7 (5):e565
    View PubMed
  26. Paulus A, Akhtar S, Caulfield TR, Samuel K, Yousaf H, Bashir Y, Paulus SM, Tran D, Hudec R, Cogen D, Jiang J, Edenfield B, Novak A, Ansell SM, Witzig T, Martin P, Coleman M, Roy V, Ailawadhi S, Chitta K, Linder S, Chanan-Khan A. Coinhibition of the deubiquitinating enzymes, USP14 and UCHL5, with VLX1570 is lethal to ibrutinib- or bortezomib-resistant Waldenstrom macroglobulinemia tumor cells. Blood Cancer J. 2016 Nov 4; 6 (11):e492 Epub 2016 Nov 04
    View PubMed
  27. Wang X, Mazurkiewicz M, Hillert EK, Olofsson MH, Pierrou S, Hillertz P, Gullbo J, Selvaraju K, Paulus A, Akhtar S, Bossler F, Khan AC, Linder S, D'Arcy P. Corrigendum: The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci Rep. 2016 Jul 29; 6:30667 Epub 2016 July 29
    View PubMed
  28. Wang X, Mazurkiewicz M, Hillert EK, Olofsson MH, Pierrou S, Hillertz P, Gullbo J, Selvaraju K, Paulus A, Akhtar S, Bossler F, Khan AC, Linder S, D'Arcy P. The proteasome deubiquitinase inhibitor VLX1570 shows selectivity for ubiquitin-specific protease-14 and induces apoptosis of multiple myeloma cells. Sci Rep. 2016 Jun 6; 6:26979 Epub 2016 June 06
    View PubMed
  29. Ailawadhi S, Paulus A, Chanan-Khan A. Preclinical models of Waldenstrom's macroglobulinemia and drug resistance. Best Pract Res Clin Haematol. 2016 Jun; 29 (2):169-178 Epub 2016 Sept 04
    View PubMed
  30. Paulus A, Ailawadhi S, Chanan-Khan A. Novel therapeutic targets in Waldenstrom macroglobulinemia. Best Pract Res Clin Haematol. 2016 Jun; 29 (2):216-228 Epub 2016 Sept 07
    View PubMed
  31. Wang X, D'Arcy P, Caulfield TR, Paulus A, Chitta K, Mohanty C, Gullbo J, Chanan-Khan A, Linder S. Synthesis and evaluation of derivatives of the proteasome deubiquitinase inhibitor b-AP15. Chem Biol Drug Des. 2015 Nov; 86 (5):1036-48 Epub 2015 May 27
    View PubMed
  32. Advani P, Paulus A, Murray P, Jiang L, Goff R, Pooley R, Jain M, Garner H, Foran J. A rare case of primary high-grade large B-cell lymphoma of the sciatic nerve. Clin Lymphoma Myeloma Leuk. 2015 Jun; 15: (6)e117-20.
    View PubMed
  33. Chitta K, Paulus A, Akhtar S, Blake MK, Caulfield TR, Novak AJ, Ansell SM, Advani P, Ailawadhi S, Sher T, Linder S, Chanan-Khan A. Targeted inhibition of the deubiquitinating enzymes, USP14 and UCHL5, induces proteotoxic stress and apoptosis in Waldenström macroglobulinaemia tumour cells. Br J Haematol. 2015 May; 169(3):377-90. Epub 2015 Feb 17.
    View PubMed
  34. Paulus A, Chitta KS, Wallace PK, Advani PP, Akhtar S, Kuranz-Blake M, Ailawadhi S, Chanan-Khan AA. Immunophenotyping of Waldenströms macroglobulinemia cell lines reveals distinct patterns of surface antigen expression: potential biological and therapeutic implications. PLoS One. 2015; 10(4):e0122338. Epub 2015 Apr 08.
    View PubMed
  35. Chitta K, Paulus A, Caulfield TR, Akhtar S, Blake MK, Ailawadhi S, Knight J, Heckman MG, Pinkerton A, Chanan-Khan A. Nimbolide targets BCL2 and induces apoptosis in preclinical models of Waldenströms macroglobulinemia. Blood Cancer J. 2014 Nov 07; 4:e260.
    View PubMed
  36. Paulus A, Masood A, Miller KC, Khan AN, Akhtar D, Advani P, Foran J, Rivera C, Roy V, Colon-Otero G, Chitta K, Chanan-Khan A. The investigational agent MLN2238 induces apoptosis and is cytotoxic to CLL cells in vitro, as a single agent and in combination with other drugs. Br J Haematol. 2014 Apr; 165: (1)78-88.
    View PubMed
  37. Chitta KS, Khan AN, Ersing N, Swaika A, Masood A, Paulus A, Qadeer A, Advani P, Sher T, Miller KC, Lee K, Chanan-Khan AA. Neem leaf extract induces cell death by apoptosis and autophagy in B-chronic lymphocytic leukemia cells. Leuk Lymphoma. 2014 Mar; 55: (3)652-61.
    View PubMed
  38. Paulus A, Chitta K, Akhtar S, Personett D, Miller KC, Thompson KJ, Carr J, Kumar S, Roy V, Ansell SM, Mikhael JR, Dispenzieri A, Reeder CB, Rivera CE, Foran J, Chanan-Khan A. AT-101 downregulates BCL2 and MCL1 and potentiates the cytotoxic effects of lenalidomide and dexamethasone in preclinical models of multiple myeloma and Waldenstrom macroglobulinaemia. Br J Haematol. 2014 Feb; 164 (3):352-365 Epub 2013 Nov 17
    View PubMed
  39. Chanan-Khan AA, Swaika A, Paulus A, Kumar SK, Mikhael JR, Rajkumar SV, Dispenzieri A, Lacy MQ. Pomalidomide: the new immunomodulatory agent for the treatment of multiple myeloma. Blood Cancer J. 2013 Sep 6; 3:e143 Epub 2013 Sept 06
    View PubMed
  40. Chitta KS, Paulus A, Ailawadhi S, Foster BA, Moser MT, Starostik P, Masood A, Sher T, Miller KC, Iancu DM, Conroy J, Nowak NJ, Sait SN, Personett DA, Coleman M, Furman RR, Martin P, Ansell SM, Lee K, Chanan-Khan AA. Development and characterization of a novel human Waldenstrom macroglobulinemia cell line: RPCI-WM1, Roswell Park Cancer Institute - Waldenstrom Macroglobulinemia 1. Leuk Lymphoma. 2013 Feb; 54 (2):387-96 Epub 2012 Aug 27
    View PubMed
  41. Swaika A, Paulus A, Miller KC, Sher T, Almyroudis NG, Ball D, Wood M, Masood A, Lee K, Chanan-Khan AA. Acyclovir prophylaxis against varicella zoster virus reactivation in multiple myeloma patients treated with bortezomib-based therapies: a retrospective analysis of 100 patients. J Support Oncol. 2012 Jul-Aug; 10: (4)155-9.
    View PubMed
  42. Masood A, Chitta K, Paulus A, Khan AN, Sher T, Ersing N, Miller KC, Manfredi D, Ailawadhi S, Borrelo I, Lee KP, Chanan-Khan A. Downregulation of BCL2 by AT-101 enhances the antileukaemic effect of lenalidomide both by an immune dependant and independent manner. Br J Haematol. 2012 Apr; 157: (1)59-66.
    View PubMed
  43. Chanan-Khan AA, Chitta K, Ersing N, Paulus A, Masood A, Sher T, Swaika A, Wallace PK, Mashtare TL Jr, Wilding G, Lee K, Czuczman MS, Borrello I, Bangia N. Biological effects and clinical significance of lenalidomide-induced tumour flare reaction in patients with chronic lymphocytic leukaemia: in vivo evidence of immune activation and antitumour response. Br J Haematol. 2011 Nov; 155: (4)457-67.
    View PubMed
  44. Advani PP, Paulus A, Masood A, Sher T, Chanan-Khan A. Pharmacokinetic evaluation of oblimersen sodium for the treatment of chronic lymphocytic leukemia. Expert Opin Drug Metab Toxicol. 2011 Jun; 7: (6)765-74.
    View PubMed
  45. Paulus A, Masood A, Advani P, Sher T, Chitta K, Chanan-Khan A. Elotuzumab, a humanized monoclonal antibody against the CD2 cell surface glycoprotein CS1 for the treatment of multiple myeloma Thomson Reuters Drug Profiles. 2011.
  46. Paulus A, Swaika A, Miller KC, Spangenthal EJ, Guo R, Vonfricken K, Lee K, Chanan-Khan AA. Clinical relapse in a patient with multiple myeloma presenting as an atrial plasmacytoma. J Clin Oncol. 2011 Jan 20; 29: (3)e47-9.
    View PubMed
  47. Masood A, Sher T, Paulus A, Miller KC, Chitta KS, Chanan-Khan A. Targeted treatment for chronic lymphocytic leukemia. Onco Targets Ther. 2011; 4:169-83.
    View PubMed